Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millenniumNarcisa Mesaros, Françoise Van Bambeke, Patrice Nordmann et al.|Clinical Microbiology and Infection|2007Cited by 575
Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Isabelle Delattre, Paul M. Tulkens, Fabio Taccone et al.|Expert Review of Anti-infective Therapy|2017Cited by 103
In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapyMickaël Riou, Y. Glupczynski, Sylviane Carbonnelle et al.|International Journal of Antimicrobial Agents|2010Cited by 76
Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital CentersHélène Thirot, Françoise Van Bambeke, Caroline Briquet et al.|Antibiotics|2021Cited by 40
Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centersHélène Thirot, Françoise Van Bambeke, David Fage et al.|Frontiers in Pharmacology|2024Cited by 13